Cystobactamids: Myxobacterial Topoisomerase Inhibitors Exhibiting Potent Antibacterial Activity

被引:144
作者
Baumann, Sascha [1 ,3 ]
Herrmann, Jennifer [1 ,3 ]
Raju, Ritesh [1 ,3 ]
Steinmetz, Heinrich [2 ,3 ]
Mohr, Kathrin I. [2 ,3 ]
Huettel, Stephan [1 ,3 ]
Harmrolfs, Kirsten [1 ,3 ]
Stadler, Marc [2 ,3 ]
Mueller, Rolf [1 ,3 ]
机构
[1] Univ Saarland, Abt Mikrobielle Nat Stoffe, Helmholtz Inst Pharmazeut Forsch Saarland, Helmholtz Zentrum Infekt Forsch, D-66123 Saarbrucken, Germany
[2] Helmholtz Zentrum Infekt Forsch, D-38124 Braunschweig, Germany
[3] DZIF, Standort Hannover Brauns, Germany
关键词
antibiotics; myxobacteria; natural products; NRPS; topoisomerase inhibitors; QUINOLONE RESISTANCE; DNA GYRASE; ESCHERICHIA-COLI; BAD BUGS; IMPACT; DRUGS; ANTIBIOTICS; DISCOVERY;
D O I
10.1002/anie.201409964
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The development of new antibiotics faces a severe crisis inter alia owing to a lack of innovative chemical scaffolds with activities against Gram-negative and multiresistant pathogens. Herein, we report highly potent novel antibacterial compounds, the myxobacteria-derived cystobactamids 1-3, which were isolated from Cystobacter sp. and show minimum inhibitory concentrations in the low mu gmL(-1) range. We describe the isolation and structure elucidation of three congeners as well as the identification and annotation of their biosynthetic gene cluster. By studying the self-resistance mechanism in the natural producer organism, the molecular targets were identified as bacterial type IIa topoisomerases. As quinolones are largely exhausted as a template for new type II topoisomerase inhibitors, the cystobactamids offer exciting alternatives to generate novel antibiotics using medicinal chemistry and biosynthetic engineering.
引用
收藏
页码:14605 / 14609
页数:5
相关论文
共 22 条
[1]   Impact of gyrA and parC mutations on quinolone resistance, doubling time, and supercoiling degree of Escherichia coli [J].
Bagel, S ;
Hüllen, V ;
Wiedemann, B ;
Heisig, P .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (04) :868-875
[2]   Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America [J].
Boucher, Helen W. ;
Talbot, George H. ;
Bradley, John S. ;
Edwards, John E., Jr. ;
Gilbert, David ;
Rice, Louis B. ;
Scheld, Michael ;
Spellberg, Brad ;
Bartlett, John .
CLINICAL INFECTIOUS DISEASES, 2009, 48 (01) :1-12
[3]   The quinolones: decades of development and use [J].
Emmerson, AM ;
Jones, AM .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 51 :13-20
[4]   Antibiotics for Emerging Pathogens [J].
Fischbach, Michael A. ;
Walsh, Christopher T. .
SCIENCE, 2009, 325 (5944) :1089-1093
[5]  
Fisher L. Mark, 2008, V142, P11, DOI 10.1007/978-1-59745-246-5_2
[6]   THE EXPORT OF THE DNA-REPLICATION INHIBITOR MICROCIN B17 PROVIDES IMMUNITY FOR THE HOST-CELL [J].
GARRIDO, MD ;
HERRERO, M ;
KOLTER, R ;
MORENO, F .
EMBO JOURNAL, 1988, 7 (06) :1853-1862
[7]   Clinical and economic impact of common multidrug-resistant gram-negative bacilli [J].
Giske, Christian G. ;
Monnet, Dominique L. ;
Cars, Otto ;
Carmeli, Yehuda .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (03) :813-821
[8]   A mutation in Escherichia coli DNA gyrase conferring quinolone resistance results in sensitivity to drugs targeting eukaryotic topoisomerase II [J].
Gruger, T ;
Nitiss, JL ;
Maxwell, A ;
Zechiedrich, EL ;
Heisig, P ;
Seeber, S ;
Pommier, Y ;
Strumberg, D .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (12) :4495-4504
[9]   New strategies and compounds for anti-infective treatment Editorial overview [J].
Hancock, Robert E. W. ;
Sahl, Hans-Georg .
CURRENT OPINION IN MICROBIOLOGY, 2013, 16 (05) :519-521
[10]   The phytotoxin albicidin is a novel inhibitor of DNA gyrase [J].
Hashimi, Saeed M. ;
Wall, Melisa K. ;
Smith, Andrew B. ;
Maxwell, Anthony ;
Birch, Robert G. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (01) :181-187